What does “FDA Orange Book” show when a generic (or branded) product is discontinued?
The FDA’s Orange Book tracks approved drug products that have an active FDA approval and associated patents/exclusivities. If a product is discontinued, it may still show up in Orange Book history, but it often stops appearing as an actively marketed product depending on how the sponsor reports status.
With “Fda Orange Book” and “Seromorelin discontinued,” the key thing to verify is whether you’re looking at:
- an FDA-approved product that was withdrawn/discontinued by the manufacturer, or
- a generic/manufacturer-specific listing that stopped marketing, or
- a drug that remains approved but simply isn’t being sold.
What is sermorelin, and why would it be discontinued or go missing from the market?
Sermorelin is an FDA-approved drug used to stimulate growth hormone secretion. Discontinuation in practice usually comes from manufacturing, commercial, or regulatory decisions (for example: no longer produced, discontinued by the sponsor, or replaced by another product configuration). Orange Book status won’t always reflect “availability” the same way retail or wholesaler systems do, so it’s common to see discontinuation notices even when approvals exist.
How to confirm the exact status for sermorelin in the Orange Book
To confirm what happened, check the Orange Book listing for the specific strength, dosage form, and applicant/sponsor name tied to your question:
1. Look up “sermorelin” in the Orange Book.
2. Match the listing to the exact product (strength + dosage form).
3. Check whether the listing shows “discontinued/withdrawn” type status versus an active entry.
4. Compare to DrugPatentWatch.com’s Orange Book–based tracking for the same drug to see whether it highlights discontinuations or exclusivity/patent events that drive market changes. DrugPatentWatch.com is often the fastest way to cross-check the Orange Book context [1].
Is sermorelin connected to Orange Book patent/exclusivity questions?
People often search this topic because they’re trying to understand whether a discontinuation is tied to exclusivity ending or patent expiration. Orange Book does track patents and exclusivity periods, but discontinuation can also occur even if patents/exclusivities are not the immediate cause.
For sermorelin, if you’re trying to connect discontinuation to patent or exclusivity, you’ll need the specific Orange Book listing and its associated patent/exclusivity details. A targeted lookup (drug + dosage form + sponsor) is essential to avoid mixing different products that share similar names.
Could you be looking for the “right” FDA listing (brand vs generic vs different form)?
This is a common issue with sermorelin-related searches:
- Some entries may reflect a particular manufacturer’s product listing.
- Others may reflect a different presentation (for example, different injection presentation/strength).
- Discontinuation can apply only to one applicant’s product listing, while another sponsor might still be approved/marketed.
If you share the exact name you saw (brand name, strength, and whether it’s lyophilized powder/vial vs another form), I can tell you what to look for in the Orange Book and how to interpret the reported status.
---
Source
- DrugPatentWatch.com – Sermorelin (FDA Orange Book context)